--- title: "Robbins LLP Reminds NUTX Investors with Large Losses of the Pending Class Action Against Nutex Health Inc. and Urges Stockholders to Contact the Firm for More Information" description: "Robbins LLP is reminding investors of a class action against Nutex Health Inc. (NASDAQ: NUTX) for alleged fraud related to its third-party arbitration vendor, HaloMD. The class action covers those who" type: "news" locale: "en" url: "https://longbridge.com/en/news/255680434.md" published_at: "2025-09-02T22:05:32.000Z" --- # Robbins LLP Reminds NUTX Investors with Large Losses of the Pending Class Action Against Nutex Health Inc. and Urges Stockholders to Contact the Firm for More Information > Robbins LLP is reminding investors of a class action against Nutex Health Inc. (NASDAQ: NUTX) for alleged fraud related to its third-party arbitration vendor, HaloMD. The class action covers those who acquired Nutex securities between August 8, 2024, and August 14, 2025. Allegations include failure to disclose fraudulent activities that inflated revenues and misrepresented financial controls. Following a report questioning Nutex's revenue legitimacy, the stock price fell over 16% after the company announced a delay in filing quarterly financial statements. Shareholders can contact Robbins LLP for more information on participating in the class action. SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Nutex Health Inc. (NASDAQ: NUTX) securities between August 8, 2024 and August 14, 2025. Nutex is a physician-led, healthcare services and operations company that began publicly trading via a reverse merger in April 2022. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. **The Allegations:** Robbins LLP is Investigating Allegations that Nutex Health Inc. (NUTX) Failed to Disclose Fraud Committed by its Third-Party Arbitration Vendor According to the complaint, during the class period, defendants failed to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vii) accordingly, Nutex’s business and/or financial prospects were overstated. The complaint alleges that on July 22, 2025, Blue Orca Capital published a short report raising concerns about Nutex's recent 20-fold share price surge. The report alleges that the Company's growth was artificially driven by a third-party arbitration vendor, HaloMD, which facilitated inflated out-of-network billing awards. According to Blue Orca, multiple federal lawsuits now allege that HaloMD orchestrated a fraudulent and racketeering scheme that siphoned millions from insurers, casting doubt on the legitimacy of Nutex's reported revenue increases. Blue Orca contends that if the revenue benefits from HaloMD's billing practices cease, Nutex's financial performance could collapse, potentially returning its stock to penny-stock levels. Then on August 14, 2025, Nutex announced it would delay filing its quarterly financial statements for the period ending June 30, 2025, citing incomplete accounting adjustments. On this news, the price of Nutex's stock fell over 16%. **What Now**: You may be eligible to participate in the class action against Nutex Health Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. ***All representation is on a contingency fee basis. Shareholders pay no fees or expenses.*** **About Robbins LLP**: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Nutix Health Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ ### Related Stocks - [NUTX.US - Nutex Health](https://longbridge.com/en/quote/NUTX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 馬斯克旗下 Grok 美國市佔升至近 18% 未受傳播色情內容影響 | 馬斯克旗下的 AI 聊天機器人 Grok 在美國的市場份額已升至近 18%，成為第三大聊天機器人，僅次於 ChatGPT 和 Google Gemini。儘管 Grok 捲入生成色情內容的爭議，但其使用率未受影響。分析師認為，社交媒體平台 | [Link](https://longbridge.com/en/news/275965405.md) | | 市場監管總局約談阿里巴巴、抖音、百度、騰訊、京東、美團、淘寶閃購等平台企業 | 市場監管總局於 2 月 13 日約談了阿里巴巴、抖音、百度、騰訊、京東、美團和淘寶閃購等平台企業，要求它們遵守相關法律法規，落實主體責任，規範促銷行為，並杜絕 “內卷式” 競爭，以維護公平競爭市場環境，促進平台經濟的創新與健康發展。 | [Link](https://longbridge.com/en/news/275975190.md) | | 每千次展示 60 美元！OpenAI 用高價拉開 “AI 廣告” 大幕 | 為應對 AI 鉅額開支，OpenAI 正式測試廣告，CPM60 美元起步、最低投入 20 萬美元，定位高端渠道，直接挑戰谷歌萬億美元市場，WPP 等頂級代理已率先合作。但轉型風險並存：需平衡用户信任，承諾不用私聊數據；對手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) | | 羣核科技拿下境外備案，“杭州六小龍” 首家上市公司漸近 | | [Link](https://longbridge.com/en/news/275974694.md) | | 中金公司重申對蔚來汽車 A 類股票（9866）的買入評級 | 中金公司分析師昨日對蔚來汽車（NIO Inc. Class A）維持了買入評級，並設定了 50.00 港元的目標價。情人節促銷 - 70% 折扣解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策。通過最新的新聞和分析保持市 | [Link](https://longbridge.com/en/news/275967598.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.